These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2040125)

  • 1. Fluconazole: a new antifungal agent.
    Kowalsky SF; Dixon DM
    Clin Pharm; 1991 Mar; 10(3):179-94. PubMed ID: 2040125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P&T Committee review of fluconazole: an effective alternative to antifungal therapy.
    Neu HC; Bennett JE; Bodey GP; Rubin RH; Schentag JJ; Sugar AM
    Hosp Formul; 1990 Mar; 25 Suppl B():9-14. PubMed ID: 10103976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
    Grant SM; Clissold SP
    Drugs; 1990 Jun; 39(6):877-916. PubMed ID: 2196167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The triazole antifungal agents: a review of itraconazole and fluconazole.
    Bailey EM; Krakovsky DJ; Rybak MJ
    Pharmacotherapy; 1990; 10(2):146-53. PubMed ID: 2161523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current drug therapy of systemic mycoses: a review.
    Yonga G
    East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral antifungals and their clinical implications.
    Heykants J; Van Peer A; Lavrijsen K; Meuldermans W; Woestenborghs R; Cauwenbergh G
    Br J Clin Pract Suppl; 1990 Sep; 71():50-6. PubMed ID: 1965419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluconazole: a new triazole antifungal agent.
    Pasko MT; Piscitelli SC; Van Slooten AD
    DICP; 1990 Sep; 24(9):860-7. PubMed ID: 2260347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current progress in antifungal therapy: the value of fluconazole].
    Meunier F
    Rev Med Brux; 1990 Sep; 11(7):278-82. PubMed ID: 2218209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
    Goa KL; Barradell LB
    Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing strategies for treatment of systemic mycoses.
    Graybill JR
    Braz J Infect Dis; 2000 Apr; 4(2):47-54. PubMed ID: 11012295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluconazole: pharmacokinetics and indications.
    Montero-Gei F
    Arch Med Res; 1993; 24(4):377-85. PubMed ID: 8118162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fluconazole--a new antifungal agent].
    Dobloug JH
    Tidsskr Nor Laegeforen; 1992 Jun; 112(15):1961-3. PubMed ID: 1509458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
    Debruyne D
    Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluconazole vs amphotericin B: "in vitro" comparative evaluation of the minimal inhibitory concentration (MIC) against yeasts isolated from AIDS patients.
    Lombardi G; Gramegna G; Cavanna C; Michelone G
    Microbiologica; 1990 Jul; 13(3):201-6. PubMed ID: 2273982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of candidiasis and cryptococcosis in AIDS].
    Just-Nübling G
    Mycoses; 1994; 37 Suppl 2():56-63. PubMed ID: 7609745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions.
    Yu DT; Peterson JF; Seger DL; Gerth WC; Bates DW
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):755-67. PubMed ID: 15654717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
    Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
    Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Choice and use of antifungal drugs].
    Dupont B
    Rev Prat; 2001 Apr; 51(7):752-7. PubMed ID: 11387672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole: a new triazole antifungal agent.
    Morrow JD
    Am J Med Sci; 1991 Aug; 302(2):129-32. PubMed ID: 1897559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.